Company intelligence / Profile preview
Aimmune Therapeutics
Brisbane, California, United Statesaimmune.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Aimmune developed Palforzia, the first FDA-approved oral immunotherapy for peanut allergy. Clinical trials demonstrated significant desensitization and protection against accidental exposure in children with peanut allergies. Additional candidates are in clinical development for egg and cow's milk allergies.[2][4][5]
- Therapeutic areas
- Immunology
- Modalities
- Oral immunotherapy (OIT)Characterized Oral Desensitization ImmunoTherapy (CODIT™)
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Nestlé Health Science US Holdings, Inc. (strategic collaboration and parent company)Regeneron Ireland Unlimited Company & Sanofi Biotechnology SAS – clinical collaboration to study Palforzia with dupilumab in peanut-allergic patients [5]
Beyond the preview
Go deeper on Aimmune Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aimmune Therapeutics.